Literature DB >> 33967056

Six-Month Community-Based Brisk Walking and Balance Exercise Alleviates Motor Symptoms and Promotes Functions in People with Parkinson's Disease: A Randomized Controlled Trial.

Margaret K Y Mak1, Irene S K Wong-Yu1.   

Abstract

BACKGROUND: In Parkinson's disease (PD), sustained aerobic exercise is a promising therapy in delaying motor disability. Brisk walking is a moderate intensity aerobic training, which could be translated to community practice at low cost, but its effects on motor symptoms remains unclear.
OBJECTIVE: To determine the effectiveness of a six-month brisk walking and balance program in alleviating motor symptoms, and promoting functional, gait, and balance performance in people with PD.
METHODS: Seventy individuals with mild to moderate PD were randomly assigned to a brisk walking (BW) group or an active control (CON) group. BW group received ten 90-minute supervised brisk walking and balance exercise for six months (weeks 1-6: once/week, weeks 7-26: once/month). CON group received upper limb training. Both groups performed 2-3 self-practice sessions weekly. Primary outcome was Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score. Secondary outcomes were fast gait speed (FGS), timed-up-and-go (TUG) time, six-minute walk distance (6MWD), and Mini-Balance Evaluation Systems Test (Mini-BEST) score.
RESULTS: Sixty-four participants (33 BW/31 CON) completed training. BW group showed greater significant decreases from baseline than CON group in MDS-UPDRS motor score after six weeks (-5.5 vs -1.6, p < 0.001) and 6 months (-6.0 vs -1.4, p < 0.001) of training. BW group also showed greater significant improvement from the baseline than CON group for TUG time, FGS, 6MWD, and mini-BEST score (all p < 0.05).
CONCLUSION: The six-month brisk walking and balance program alleviates motor symptoms, promotes functional and gait performance, walking capacity, and dynamic balance in people with mild to moderate PD.

Entities:  

Keywords:  Parkinson’s disease; aerobic exercise; postural balance; recovery of function; rehabilitation

Mesh:

Year:  2021        PMID: 33967056     DOI: 10.3233/JPD-202503

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  4 in total

1.  Is Being Physically Active Enough or Do People with Parkinson's Disease Need Structured Supervised Exercise? Lessons Learned from COVID-19.

Authors:  Josefa Domingos; Carlos Família; Júlio Belo Fernandes; John Dean; Catarina Godinho
Journal:  Int J Environ Res Public Health       Date:  2022-02-19       Impact factor: 3.390

2.  Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson's disease patients.

Authors:  Gen Li; Pei Huang; Shi-Shuang Cui; Yu-Yan Tan; Ya-Chao He; Xin Shen; Qin-Ying Jiang; Ping Huang; Gui-Ying He; Bin-Yin Li; Yu-Xin Li; Jin Xu; Zheng Wang; Sheng-Di Chen
Journal:  Transl Neurodegener       Date:  2022-02-07       Impact factor: 8.014

3.  Physical Therapy for at Least 6 Months Improves Motor Symptoms in Parkinson's Patients: A Meta-Analysis.

Authors:  Xiaotian Ji; Danian Lu; Qinglan Yang; Linting Xiao; Jing Wang; Gaiqing Wang
Journal:  Comput Math Methods Med       Date:  2022-07-31       Impact factor: 2.809

4.  Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.

Authors:  Charity G Patterson; Elizabeth Joslin; Alexandra B Gil; Wendy Spigle; Todd Nemet; Lana Chahine; Cory L Christiansen; Ed Melanson; Wendy M Kohrt; Martina Mancini; Deborah Josbeno; Katherine Balfany; Garett Griffith; Mac Kenzie Dunlap; Guillaume Lamotte; Erin Suttman; Danielle Larson; Chantale Branson; Kathleen E McKee; Li Goelz; Cynthia Poon; Barbara Tilley; Un Jung Kang; Malú Gámez Tansey; Nijee Luthra; Caroline M Tanner; Jacob M Haus; Giamila Fantuzzi; Nikolaus R McFarland; Paulina Gonzalez-Latapi; Tatiana Foroud; Robert Motl; Michael A Schwarzschild; Tanya Simuni; Kenneth Marek; Anna Naito; Codrin Lungu; Daniel M Corcos
Journal:  Trials       Date:  2022-10-06       Impact factor: 2.728

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.